To empower clinicians and help patients with the best predictive information for personalized cancer care

ImpriMed co-founders Sungwon Lim and Jamin Koo met as undergraduates and discovered a shared passion for developing advanced technologies to improve the treatment of disease.  Both went on to complete PhDs in engineering sciences at Stanford University, where they decided to launch a startup company to tackle one of the greatest challenges in human disease: cancer.  

In 2017, Sungwon and Jamin founded ImpriMed to provide immediate solutions for cancer patients who need effective treatments today.

Rather than focusing on the development of new drugs for future patients, they built a platform that enables oncologists to quickly identify which of the available drugs can provide the best clinical outcomes for current patients. The ImpriMed platform combines quantitative high-throughput lab testing and artificial intelligence (AI) to provide healthcare providers with a comprehensive personalized drug prediction profile. Our AI models are trained using ImpriMed’s proprietary database of real-world clinical outcomes and a suite of lab tests that include our innovative ex vivo drug sensitivity assay that measures how a patient’s live tumor cells respond to a panel of anticancer drugs.  

We first launched the ImpriMed platform in the veterinary oncology space which moves at a significantly higher speed than the human oncology market and allows easy access to comprehensive patient data. ImpriMed has helped 200+ veterinary oncologists in 30 states to deliver personalized treatments to their canine lymphoma and leukemia patients. Apart from providing veterinarians with a cutting-edge tool to help man’s best friend, ImpriMed’s experience in the veterinary market has paved the way for the company to launch its validated platform into the human oncology space.

At ImpriMed, we are saving pet cancer patients now, and we will save pet parents next!